Trilogy delivers modest growth in H1 FY18

Company News

by Kathy Skantzos

Natural skincare company Trilogy (ASX:TIL) has reported its first half FY2018 revenue has increased 4 per cent to $49.7 million, however EBITDA declined by nearly $1 million to $6.3 million.

CEO Angela Buglass said the company delivered modest growth in the first half despite retail market pressure in its home markets of Australia and New Zealand, and delivered in its strategy to grow international markets, which grew 235 per cent over last year.

The company’s natural products segment delivered $18.7 million in revenue, an increase of 4.8 per cent, however its home fragrance and bodycare segment declined 7.3 per cent to $8.3 million.

The company said cost impacts and short-term quality issues impacted the group’s profitability, however added it has started implementing initiatives to accelerate growth in the second half to keep on track with its guidance.

The company said the group’s complementary skincare brand Lanocorp is progressing as expected, with its three month contribution delivering $3.1 million.

Shares in Trilogy (ASX:TIL) closed 2.13 per cent lower to $2.30.

Kathy Skantzos

Finance News Network
Kathy presents the Market Outlook and ASX company news. She joined FNN in September 2017. She has been in print and online journalism for over 9 years. She also worked in corporate communications.